NDAORALCAPSULE, EXTENDED RELEASE
Approved
Aug 2017
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
14
Data completeness
7/8 — Comprehensive
GOCOVRI (amantadine) by Supernus Pharmaceuticals is m2 protein inhibitors [moa]. Approved for schizophrenia. First approved in 2017.
Drug data last refreshed 19h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GOCOVRI is an extended-release oral capsule formulation of amantadine, an M2 protein inhibitor developed by Supernus Pharmaceuticals and approved in August 2017. It is indicated for the treatment of Parkinson's disease, drug-induced extrapyramidal reactions, and uncomplicated respiratory tract illness caused by influenza A virus. The drug works by inhibiting the influenza A M2 protein and modulating dopaminergic activity in the central nervous system. GOCOVRI occupies a mature position in the Parkinson's disease market, where it serves as an adjunctive therapy alongside dopamine agonists and levodopa-based regimens.
$0.1BPart D
12.3 years to LOEMechanism of Action
M2 Protein Inhibitors
Pharmacologic Class:
Influenza A M2 Protein Inhibitor
Indications (1)
Clinical Trials (14)
Use of Gocovri to Improve Disability Due to Radiation Encephalopathy
Started Sep 2025
24 enrolled
Radiation Encephalopathy
Acetyl-Amantadine as a Biomarker in Patients With Glioblastoma
Started Dec 2020
20 enrolled
Glioblastoma Multiforme
Effect of GOCOVRI (Amantadine, Extended Release Capsules) on Gait in Parkinson's Disease
Started Nov 2020
8 enrolled
Parkinson Disease
Buspirone, in Combination With Amantadine, for the Treatment of Levodopa-induced Dyskinesia
Started Jan 2016
6 enrolled
Parkinson's DiseaseDyskinesiasMovement Disorders
Effect of Intravenous Amantadine on Gait Freezing in Parkinson's Disease
Started Feb 2011
46 enrolled
Parkinson's Disease
Worked on GOCOVRI at Supernus Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.